


Measles and rubella elimination country profile Uzbekistan

Measles elimination status

2016 eliminated
2017 eliminated




Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrv

Measles and rubella surveillance

National case-based surveillance for measles, rubella and CRS

Lab confirmation for diagnosis of measles, rubella and CRS



Source: WHO/UNICEF Joint Reporting Form on Immunization, 2017

Measles and rubella immunization schedule, 2017

	Vaccine	Schedule	Year of introduction	
MCV1	MMR	1 year	MCV2	1986
MCV2	MMR	6 years	RCV	2006
Measles vaccination in school				Yes

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/)

MMR = measles-mumps-rubella vaccine; MCV1 = first dose measles-containing vaccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine

Definition used for an outbreak

ND




Source: Measles and rubella elimination Annual Status Update report, 2017
ND = Data not available



Rubella elimination status

2016 eliminated
2017 eliminated




Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrv

Demographic information, 2017

Total population	31 910 641
< 1 year old	618 511
< 5 years old	3 180 209

Source: World Population Prospects: The 2017 Revision, New York, United Nations

Measles and rubella cases and immunization coverage, 2008–2017




Source: Disease incidence and immunization coverage (WUENIC), WHO, Data and Statistics, Immunization Monitoring and Surveillance

(http://www.who.int/immunization/monitoring_surveillance/data/en/)

MCV1 = first dose of measles-containing vaccine
MCV2 = second dose of measles-containing vaccine

Confirmed measles cases by month of onset, 2013-2017



Source: CISD 2017

Measles and rubella elimination country profile Uzbekistan

Measles incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected measles cases	Confirmed measles cases				Discarded as non-measles	Measles incidence	Genotypes detected
		Laboratory	Epi- linked	Clinically	Total			
2013	8	0	0	0	0	8	0	NA
2014	29	8	0	0	8	21	0.3	B3,D8
2015	52	22	0	0	22	34	0.1	D8
2016	135	1	0	0	1	134	0	ND
2017	59	0	0	0	0	59	0	NA

Source: Measles and rubella elimination Annual Status Update report, 2013-2017
Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable

Measles surveillance and laboratory performance indicators, 2013-2017

	Discarded non-measles rate	% 1st sub-national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for measles	% positive for measles	Rate of viral detection	% WHO and proficient labs
2013	0.2	0%	100%	ND	8	0%	ND	100%
2014	0.6	0%	100%	100%	50	16%	25%	100%
2015	1	0%	100%	100%	85	25.9%	22.7%	100%
2016	4.1	0%	100%	100%	152	0.7%	0%	100%
2017	0.3	12.5%	100%	NA	82	0%	NA	100%

Source: ASU 2013-2017
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

Rubella incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected rubella cases	Confirmed rubella cases				Discarded as non-rubella	Rubella incidence	Genotypes detected
		Laboratory	Epi- linked	Clinically	Total			
2013	0	0	0	0	0	0	0	NA
2014	21	0	0	0	0	21	0	NA
2015	33	0	0	0	0	33	0	NA
2016	17	0	0	0	0	17	0	NA
2017	23	1	0	0	1	22	0	ND

Source: Measles and rubella elimination Annual Status Update report, 2013-2017
Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable

Rubella surveillance and laboratory performance indicators, 2013-2017

	Discarded non-rubella rate	% 1st sub-national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for rubella	% positive for rubella	Rate of viral detection	% WHO and proficient labs
2013	0	0%	100%	NA	8	0%	ND	100%
2014	0.6	0%	100%	NA	50	0%	ND	100%
2015	0.1	0%	100%	NA	85	0%	ND	100%
2016	0.5	0%	100%	NA	152	0%	ND	100%
2017	0.3	12.5%	100%	ND	82	1.2%	0%	100%

Source: ASU 2013-2017
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

RVC comments, based on 2017 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in Uzbekistan in 2017 and confirmed that measles and rubella elimination has been sustained. The RVC nevertheless urges consideration of additional activities to improve the quality of reporting and surveillance of measles, rubella and CRS. The RVC reiterates that molecular genotyping of measles and rubella viruses are crucial in the elimination period and should be performed if confirmed cases appear. The RVC anticipates that the national public health system will maintain high routine immunization coverage with coverage monitoring at subnational levels.

Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrv

Surveillance performance indicators and targets

- Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population
- % cases with adequate laboratory investigation: $\geq 80\%$
- % origin of infection known: $\geq 80\%$
- Rate of viral detection: $\geq 80\%$

Sources of infection, 2017

	Measles	Rubella
Imported	0	1
Import-related	0	0
Unknown/ Not reported	0	0
Endemic	0	0

Source: Measles and rubella elimination Annual Status Update report, 2017

Information on CRS, 2017

No cases reported

Source: Measles and rubella elimination Annual Status Update report, 2017
CRS = congenital rubella syndrome